<div id="readability-page-1"><p>Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $12.72 and last traded at $12.14, with a volume of 92947 shares. The stock had previously closed at $12.26.</p><div><p><span></span><span>Get <strong>Astellas Pharma</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><p>ALPMY has been the topic of a number of research reports. Sanford C. Bernstein lowered shares of Astellas Pharma from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Tuesday, September 2nd. Zacks Research cut shares of Astellas Pharma from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Hold rating,  According to data from MarketBeat, Astellas Pharma currently has a consensus rating of &#34;Hold&#34;.</p><p><b>Get Our Latest Analysis on Astellas Pharma</b></p><h2>Astellas Pharma Trading Down 1.0%</h2><p>The company has a market capitalization of $21.97 billion, a price-to-earnings ratio of 25.83 and a beta of 0.23. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.89 and a current ratio of 1.17. The business's 50-day simple moving average is $11.07 and its 200-day simple moving average is $10.44. </p><p>Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.20 by $0.10. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.73%. The company had revenue of $3.45 billion during the quarter, compared to analysts' expectations of $3.14 billion.  On average, research analysts expect that  Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year. </p><h2>About Astellas Pharma</h2> (Get Free Report)<p>Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.</p><h2>See Also</h2><ul><li>Five stocks we like better than Astellas Pharma</li><li>Ride Out The Recession With These Dividend Kings </li><li>Whirlpool’s Worst May Be Over—Upside Opportunity Ahead</li><li>Special Purpose Acquisition Company (SPAC) What You Need to Know </li><li>These 3 Beaten-Down Stocks Could Be Your Best Buying Opportunity This Quarter</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>How Does D-Wave Stack Up to Quantum Rivals After Earnings Season?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Astellas Pharma Right Now?</h2><p>Before you consider Astellas Pharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.</p><p>While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALPMY

<p>Astellas Pharma (OTCMKTS:ALPMY) reached a new 52-week high at $12.72, closing at $12.14 with 92,947 shares traded. Analysts have downgraded the stock to 'Hold' from 'Outperform' and 'Strong-buy'. The company reported better-than-expected quarterly earnings, with $0.30 EPS and $3.45 billion revenue. Despite the high, analysts suggest other stocks may be better buys.</p>

Astellas Pharma (OTCMKTS:ALPMY) Sets New 12-Month High - Time to Buy?